Homozygous Familial Hypercholesterolemia (HoFH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
- Published Date : November 17, 2025
- Updated On : April 9, 2026
- Pages : 154
Homozygous Familial Hypercholesterolemia (HoFH) Market Outlook
Thelansis’s “Homozygous Familial Hypercholesterolemia (HoFH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Homozygous Familial Hypercholesterolemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Homozygous Familial Hypercholesterolemia (HoFH) Overview
Homozygous familial hypercholesterolemia (HoFH) is a rare, severe autosomal codominant disorder of lipid metabolism caused by biallelic mutations in the LDLR gene, or, less commonly gain-of-function PCSK9 or APOB defects. This disrupts hepatic low-density lipoprotein receptor clearance, elevating low-density lipoprotein cholesterol levels past thirteen millimoles per liter from birth and triggering aggressive, premature cardiovascular disease in childhood. Patients develop tendon xanthomas, corneal arcus, and early myocardial infarction or aortic stenosis. Diagnosis combines clinical phenotyping, profound hypercholesterolemia, and confirmatory genetic screening. While high-dose statins and ezetimibe form the foundation, they are vastly insufficient. Standard PCSK9 inhibitors like evolocumab offer modest drops only in receptor-defective variants and fail completely in receptor-negative mutations. Consequently, management relies heavily on receptor-independent pathways. The oral microsomal triglyceride transfer protein inhibitor lomitapide provides substantial lipid reduction but requires a strict low-fat diet to mitigate gastrointestinal side effects. The therapeutic paradigm is led by Evkeeza (evinacumab), an angiopoietin-like 3 inhibitor that functions completely independently of the low-density lipoprotein receptor. Now approved down to one year of age, evinacumab delivers durable cholesterol reductions and alters long-term survival. Regular lipid panel monitoring, vascular imaging, and early specialist care are vital to prevent premature mortality.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2025–2035)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
Homozygous Familial Hypercholesterolemia (HoFH) Market Outlook
Thelansis’s “Homozygous Familial Hypercholesterolemia (HoFH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Homozygous Familial Hypercholesterolemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Homozygous Familial Hypercholesterolemia (HoFH) Overview
Homozygous familial hypercholesterolemia (HoFH) is a rare, severe autosomal codominant disorder of lipid metabolism caused by biallelic mutations in the LDLR gene, or, less commonly gain-of-function PCSK9 or APOB defects. This disrupts hepatic low-density lipoprotein receptor clearance, elevating low-density lipoprotein cholesterol levels past thirteen millimoles per liter from birth and triggering aggressive, premature cardiovascular disease in childhood. Patients develop tendon xanthomas, corneal arcus, and early myocardial infarction or aortic stenosis. Diagnosis combines clinical phenotyping, profound hypercholesterolemia, and confirmatory genetic screening. While high-dose statins and ezetimibe form the foundation, they are vastly insufficient. Standard PCSK9 inhibitors like evolocumab offer modest drops only in receptor-defective variants and fail completely in receptor-negative mutations. Consequently, management relies heavily on receptor-independent pathways. The oral microsomal triglyceride transfer protein inhibitor lomitapide provides substantial lipid reduction but requires a strict low-fat diet to mitigate gastrointestinal side effects. The therapeutic paradigm is led by Evkeeza (evinacumab), an angiopoietin-like 3 inhibitor that functions completely independently of the low-density lipoprotein receptor. Now approved down to one year of age, evinacumab delivers durable cholesterol reductions and alters long-term survival. Regular lipid panel monitoring, vascular imaging, and early specialist care are vital to prevent premature mortality.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2025–2035)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)